In depth
Polymyalgia rheumatica: common questions
Corticosteroids kill the pain fast, and that's where most explanations of this illness stop. What happens to your strength and your energy over the next two years is the part you are hardly ever warned about. That second stretch is what this whole page is built around, because the numbers on it are striking.
What the research found.
At the first visit, 71.2 percent of these patients were already heading toward frailty, against 34.4 percent in the controls. That works out at an odds ratio of 4.7 for the patient group. At follow-up, which came nearly two years after treatment began, it was still 60.7 percent.
Bad tiredness hit 36 percent of patients at the start and 35 percent at follow-up, against 3 percent in the controls. Poor sleep hit 77 percent and then 84 percent, against 56 percent in the controls. Follow-up came nearly two years after treatment started, so neither had settled with time.
The 2017 American College of Rheumatology guideline covers every adult on a long corticosteroid course, at every age. It strongly advises four things, which are getting your calcium and vitamin D right and doing weight-bearing and strength-building exercise. The other two are stopping smoking and cutting back on how much you drink.
One study looked back at patient records to see what was associated with an illness going quiet. Vitamin D rose 22.02 ng/mL over three months in the people whose illness settled, and 1.33 in the people whose illness stayed active. That rise predicted going quiet, at an odds ratio of 2.89.
One survey asked 197 patients what they did for their illness besides taking the drugs, and 41.1 percent of them did something. Fewer still exercised, at just 17.8 percent of the whole group surveyed. Only 25.4 percent had ever been told to do specific exercises for this illness, most often by a physiotherapist.
What happens after the pain goes
Polymyalgia rheumatica answers to corticosteroids fast, which is one of the more satisfying things in rheumatology. That's where most explanations of this illness stop. What happens over the next two years is the part patients don't get warned about at all.
One study followed patients for 18 months against matched controls, and the patients scored worse on a disability form at both visits. The differences came out at 0.33 and 0.41. Women with the illness slowed down more when walking than female controls, by 0.13 meters per second, and they were 3.27 seconds slower getting out of a chair at follow-up.
At the first visit, 71.2 percent of patients were heading toward frailty, against 34.4 percent in the controls, which is an odds ratio of 4.7. At follow-up it was still 60.7 percent, so the pain answering to treatment and your strength coming back are two separate events. Corticosteroids usually settle the first fast, and nothing about that guarantees the second.
Tiredness and sleep, which outlast the pain
A companion study measured tiredness and sleep in those patients. Bad tiredness hit 36 percent at the start and 35 percent at follow-up, against 3 percent in the controls. Poor sleep hit 77 percent at the start and 84 percent at follow-up, against 56 percent in the controls. Both were still there nearly two years after treatment began.
Bad tiredness was associated with a longer list than disease activity alone, because it was also associated with more weight and more body fat. It correlated with worry and low mood, and it correlated with disease activity, the blood markers, pain, and stiffness. That counts in practice, because if you read lasting tiredness as proof of uncontrolled swelling, you get corticosteroid decisions that touch only two things on that list.
What has never been tested is whether exercise changes any of it. There's no trial of exercise in this illness at all, so there's no figure to give you for tiredness or for sleep. Trying it is reasonable on the general case for staying active, and being told it's proven for this illness would be false.
The guideline that says exercise and says nothing else
Across all the illnesses on this site, this is the only one whose main society guidelines tell you outright to exercise. The European and American document says it, and so does the British one. Both back an exercise program to hold onto muscle, to hold onto function, and to cut the risk of falls. They stress it most for frail patients and for older patients on long corticosteroid courses.
Neither one says how much, what kind, how often, or how hard. That's because no exercise trial in this illness exists to put a number on. So the guidelines back exercises built for each person while having no evidence behind that advice, and what physiotherapists do for this illness has never been studied either.
That hole is worth naming. A guideline that tells you to exercise and can't tell you how is still telling you something real. What it can't do is spare you from working it out with somebody, starting from what you can do now.
What most people are offered
One survey asked 197 patients what they did besides taking drugs, and 41.1 percent of them did something, while only 17.8 percent exercised. A quarter had been told to do exercises for their illness. Most often a physiotherapist told them, and less often it was a family doctor or a hospital doctor.
Among those who changed their exercise, about 85 percent found it helped. That survey was honest about something else, because in its own data no single non-drug therapy correlated with better long-term outcomes. So feeling helped and being measurably better are still two very different things.
What that survey settles beyond doubt is that most people with this diagnosis are offered nothing at all. The guidelines say to exercise, and function stays poor for years afterward. So asking for a physiotherapy referral is a fair thing to do rather than a nuisance.
Bones, corticosteroids, and vitamin D
Anyone on a long corticosteroid course falls under the 2017 American College of Rheumatology guideline. It gives strong advice at every age, starting with calcium and vitamin D and going on to weight-bearing and strength-building exercise, stopping smoking, and drinking less. That's the most specific lifestyle wording that reaches you here, and it comes through the drug rather than the diagnosis.
The link between dose and bone density is less direct than you'd expect. One study measured 198 patients with polymyalgia rheumatica, giant cell arteritis, and other kinds of vasculitis, where the dose didn't correlate with the lowest bone score. Neither the current dose nor the total correlated with it, though three other things did. Those were being lighter, having broken a bone in the spine before, and taking a heartburn drug, which cuts against eating very little to counter corticosteroid weight gain.
Vitamin D gave this illness its most quotable finding, and the caveat has to be quoted with it. One study looked back at records, where vitamin D rose 22.02 ng/mL over three months in people whose illness went quiet and 1.33 in people whose illness stayed active. That rise predicted going quiet at an odds ratio of 2.89, and the corticosteroid dose didn't. Looking backward and only watching means it can't tell you which caused which, and every explanation fits those numbers, from how well people absorbed it to how consistently it got prescribed.
Common misconceptions.
Myth. Once the pain goes, everything else follows.
Reality. It doesn't, because patients scored worse than controls on a disability form at both visits over 18 months. At follow-up, 60.7 percent were still heading toward frailty, and about a third couldn't do what they used to after nearly two years. So the pain answering to corticosteroids and your strength coming back are two different events here.
Myth. My fatigue means the disease is still active.
Reality. Maybe not, because bad tiredness hit 36 percent at the start and 35 percent nearly two years later, when most people's illness is under control. It does correlate with disease activity and the blood markers, and it also correlates with weight, body fat, worry, low mood, pain, and stiffness. Read it as proof of active swelling and you get corticosteroid decisions touching only two things on that list.
Myth. There's a proven exercise program for this condition.
Reality. There isn't one, because both guidelines tell you to exercise and neither says how much, what kind, how often, or how hard. That's because no exercise trial in this illness exists. One paper puts it bluntly, which is that the international guidelines back exercises built for each person with no evidence behind them, and that what physiotherapists do for this illness has never been studied.
Myth. Vitamin D supplementation will drive my disease into remission.
Reality. One study looked back at records, where vitamin D rose 22.02 ng/mL over three months in people whose illness went quiet and 1.33 in people whose illness stayed active. The rise predicted going quiet, at an odds ratio of 2.89. It looked backward and it only watched, so it can't say which caused which, though fixing a low level is still worth doing on corticosteroids for your bones.
Questions patients ask.
Why do I still feel so limited when the pain has gone?
Because that's what the research shows in this illness, where patients scored worse than matched controls on a disability form at both visits over 18 months. Women slowed down more than female controls when walking, and were slower getting out of a chair at follow-up too. In all, 71.2 percent were heading toward frailty at the first visit, against 34.4 percent of controls. About a third couldn't do what they used to after nearly two years.
Is my fatigue normal?
It's very common, and it lasts longer than anybody warns you. Bad tiredness hit 36 percent of patients at the start and 35 percent at follow-up, against 3 percent in the controls. Poor sleep hit 77 percent and then 84 percent, against 56 percent. Both were still there nearly two years after treatment began, so this doesn't clear up on its own along with the pain.
Should I be exercising?
You should, and this is the only illness on this site whose main guidelines say so outright. The European and American guideline says it and so does the British one. Both back an exercise program to hold onto muscle, to hold onto function, and to cut falls, and they stress it most for frail patients and older patients on long corticosteroid courses. Neither one says how much, what kind, how often, or how hard.
So what program should I follow?
Trial evidence can't tell you that, because no exercise trial in this illness exists. The guidelines back exercises built for each person with no evidence behind them at all, and what physiotherapists do here has never been studied either. So build from what you can do now, with somebody who knows there's no protocol to follow. That's the honest route rather than a satisfying one to be handed.
Will exercise help the fatigue?
Nothing on record answers that, because no trial of exercise in this illness has been run. Tiredness and poor sleep are both well documented here, and they last a great deal longer than most people are warned about. What has never been tested anywhere is whether exercise changes either one of them. Trying it is reasonable, and calling it proven for this illness would be false.
What should I do about my bones on prednisone?
The 2017 American College of Rheumatology guideline covers anyone on a long corticosteroid course, at every age. It strongly advises getting your calcium and vitamin D right, doing weight-bearing and strength-building exercise, stopping smoking, and cutting back on alcohol. One other study is worth knowing, because it measured bone density in 198 patients and neither the current corticosteroid dose nor the total correlated with it. Being lighter did, and so did a past spine fracture and a heartburn drug.
Is there a diet for polymyalgia rheumatica?
Not one has been tested, and the treatment guidelines give no advice of their own on diet, calcium, or vitamin D. What does apply reaches you through the corticosteroids rather than the diagnosis. So anything sold as a diet for this illness is up against a very thin record, which is one vitamin D study and no trial of any diet at all.
What about the vitamin D finding?
One study looked back at records, where vitamin D rose 22.02 ng/mL over three months in people whose illness went quiet and 1.33 in people whose illness stayed active. The rise predicted going quiet, at an odds ratio of 2.89. That study looked backward and only watched what happened, so it can't tell you which of those caused which. The corticosteroid dose didn't predict it, so maybe raising the level helps, or maybe people who do well differ in some other way.
What should I take to my next appointment?
Four things need urgent care rather than a routine mention, which are a new headache, jaw pain when you chew, a tender scalp, and any change in your vision. Giant cell arteritis comes with this illness, and it can cost your sight. Past those, three things tell your team more than describing your pain does. Those are how far you can walk, whether you can get out of a chair without pushing with your arms, and how you're sleeping.
References.
- Dejaco C; Singh Y; Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases. 2015;74:1799-1807. 10.1136/annrheumdis-2015-207492International guideline
- Leung J; De Ross B; Gianoudis J et al. Changes to physical function and body composition during the first 2 years of polymyalgia rheumatica. Rheumatology. 2025;64:5834-5843. 10.1093/rheumatology/keaf375Prospective longitudinal case-control cohort
- Leung J; De Ross B; Gianoudis J et al. More Than Pain and Stiffness: Persistent Fatigue and Sleep Disturbance in Polymyalgia Rheumatica. The Journal of Rheumatology. 2025:jrheum.2024-0980. 10.3899/jrheum.2024-0980Prospective longitudinal case-control cohort
- Weddell J; Hider S; Mallen C et al. What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study. Rheumatology International. 2021;42:285-290. 10.1007/s00296-021-05036-6Primary-care inception cohort with long-term follow-up questionnaire
- O'Brien A; Muller S; Liddle J et al. Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross‐Sectional Survey. Musculoskeletal Care. 2025;23. 10.1002/msc.70155Cross-sectional survey of UK physiotherapists
- Buckley L; Guyatt G; Fink H et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. 2017;69:1521-1537. 10.1002/art.40137GRADE-based clinical practice guideline
- Hysa E; Balito S; Davoli G et al. Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation. Nutrients. 2025;17:2839. 10.3390/nu17172839Retrospective observational case-control study with a longitudinal subgroup
- Palmowski A; Wiebe E; Muche B et al. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022;11:536. 10.3390/cells11030536Cross-sectional baseline analysis of a prospective cohort
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.